As mentioned earlier, the CDKN2C gene is not regularly inactivated by deletion or point mutations in human cancer, however, loss of p18INK4c expression has been linked to the development of medulloblastomas, hepatocellular cancer, testicular cancer, and medullary thyroid carcinoma [282–286] and promotor hypermethylation of CDKN2C has been reported in gastric cancer and Hodgkin lymphomas [275, 287]. The gene discussed is CDKN2C; the disease is medullary thyroid gland carcinoma.